About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 250 record(s)
Req # A-2021-001837
The Rothmans, Benson & Hedges submission in response to the Health Canada consultation document “New Health-Related Labelling for Tobacco Products” dated October 2018.Organization: Health Canada
May 2022
Req # A-2021-001838
The JTI-Macdonald submission in response to the Health Canada consultation document “New Health-Related Labelling for Tobacco Products” dated October 2018.Organization: Health Canada
May 2022
Req # A-2021-001888
All media agreements and/or contracts regarding Public Health Canada's 11 million "Ripple Effect" advertising campaign as cited in the below media release. https://www.canada.ca/en/public-health/news/2021/05/government-of-canada-launches-new-ripple-effect-advertising-campaign-to-encourage-covid-19-vaccination.html.Organization: Health Canada
May 2022
Req # A-2021-002018
The Screening Acceptance Letter(s) from Health Canada to all & any generic drug manufacturer(s) related to all and any Abbreviated New Drug Submission(s) for the medicinal ingredient risperidone which appear(s) on the list of Generic Drug Submissions Under Review (GSUR).Organization: Health Canada
May 2022
Req # A-2022-000035
Data related the Policy on COVID-19 Vaccination for the Health Canada attestations and the accommodation requests that were submitted and approved/denied.Organization: Health Canada
May 2022
Req # A-2018-001842
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 18-109911-139.Organization: Health Canada
May 2022
Req # A-2019-000630
Adverse Drug Reactions (ADRs) for LEFLUNOMIDE. Report numbers: E2B_01861936, E2B_01865609, E2B_01893183, E2B_01935369, E2B_01895206, E2B_01893736, E2B_01937807, E2B_01892347, E2B_01892358, E2B_01938194, E2B_01815373, E2B_01464383, 000720018, E2B_01939578, E2B_01893978, E2B_01893070, E2B_01919237, E2B_01893112, E2B_01831646, E2B_01832253, E2B_01832508, E2B_01905623, E2B_01837135, E2B_01968143, E2B_01910990, E2B_01914627, E2B_01844804, E2B_01846436, E2B_01855542, E2B_01855576, E2B_01934063.Organization: Health Canada
May 2022
Req # A-2019-001476
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-118044-520.Organization: Health Canada
May 2022
Req # A-2019-001633
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-118044-520.Organization: Health Canada
May 2022
Req # A-2020-000086
Adverse Drug Reactions (ADRs) for Celexa. Report numbers: E2B_02757753, E2B_02757783, E2B_02669846, E2B_02675543, 000728695, 000728796, 000728934, E2B_02808449, E2B_02786013, E2B_02790729, E2B_02786012, E2B_02769575, E2B_02778423.Organization: Health Canada
May 2022